Osimertinib granted Breakthrough Therapy Designation in the US for the adjuvant treatment of stage IB-IIIA EGFR-mutated non-small cell lung cancer

The designation is based on data from the Phase III ADAURA trial, in which osimertinib was associated with a reduced risk of disease recurrence or death versus placebo (HR 0.21; 95% CI 0.16-0.28; p<0.0001).


Biospace Inc.